Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Activist Farpoint Capital Just Sent This Absolutely Scathing Letter to Carl Icahn

Cadus, Farpoint Capital: In a new activist stake just filed, the Texas-based Farpoint Capital disclosed a 5.2% stake in Cadus Corporation (OTCBB:KDUS). The firm also elected to send a letter to Carl Icahn, who has been Cadus’ controlling shareholder for 18 years.

In the letter, Farpoint writers to Icahn, “It appears to us that you have relegated the company to the status of an unwanted orphan in a coma who receives no visitors,” adding, “This is not the kind of performance that investors have come to expect from Carl C. Icahn. Perhaps as a twitter devotee you should share it with your followers.”

Here’s the letter in all its glory.


As mentioned in the letter, Icahn has been a controlling shareholder in the biological database provider and drug discovery company, Cadus, since the mid-nineties. The stock’s performance year-to-date has underwhelmed, and is up just 8.5% (less than many other micro-cap peers). It’s clear that Farpoint either wants Icahn to put more effort into shareholder value creation here, or it would like him to sell his shares. The firm points to these missteps in particular:

1. From 2003 to the present the share price of Cadus (KDUS) has fluctuated between $1.03 and $1.97 a share. At the current price of $1.52 a share, shareholders have seen no gain on their investment after 10 years. Adjusted for inflation, they are net losers.

2. Book value on December 31, 2003 of $2.04 a share has declined to $1.72 a share on June 30, 2013. It continues to erode at about $0.01 a share every quarter.

3. Working capital on December 31, 2003 was $26,000,000. As of June 30, 2013 it was $22,000,000.

4. Tax net operating loss carry forwards have declined due to expirations from $28,800,000 as of December 31, 2003 to $18,900,000 on December 31, 2012.

5. No year since 2003 has shown a profit.

Disclosure: none

Recommended Reading:

5 Activist Hedge Funds to Watch

The 40 Biggest Hedge Fund Billionaires

10 Activist Hedge Funds to Keep An Eye On

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!